Neurogene shares surged 25% pre-market after the FDA granted Breakthrough Therapy designation to its Rett syndrome gene therapy. The decision followed positive Phase 1/2 data. Additionally, Canaccord initiated coverage with a Buy rating and a $200 price target, citing significant upside potential as the company prepares for further clinical data readouts later this year.